Section 1 - Chemical Product and Company Identification
Ampicillin Sodium Salt Catalog Numbers:
BP1760-5, BP176025, BP17605, BP1760500GM, BP690-5, BP691-5, BP6915,
S71693R, XXBP1760500G Synonyms:
Alpen-N; Amcill-S; D-Alpha-aminobenxylpenicillin sodium salt; Ampicillin sodium salt Company Identification:
1 Reagent Lane
Fair Lawn, NJ 07410 For information, call:
201-796-7100 Emergency Number:
201-796-7100 For CHEMTREC assistance, call:
800-424-9300 For International CHEMTREC assistance, call:
Section 2 - Composition, Information on Ingredients
XN Risk Phrases:
Appearance: white to off-white solid. Warning!
May cause allergic respiratory reaction. May cause
allergic skin reaction. Sensitizer. May cause eye and skin irritation. May cause respiratory and digestive
tract irritation. Target Organs:
Respiratory system, skin.
Potential Health Effects Eye:
May cause eye irritation. Skin:
May cause skin irritation. May cause skin sensitization, an allergic reaction, which becomes
evident upon re-exposure to this material. Ingestion:
May cause gastrointestinal irritation with nausea, vomiting and diarrhea. May cause serious
or fatal hypersensitivity (anaphylactic) reactions in some individuals. Inhalation:
May cause allergic respiratory reaction. May cause respiratory tract irritation. Chronic:
May cause reproductive and fetal effects.
Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper
and lower eyelids. Get medical aid immediately. Skin:
Immediately flush skin with plenty of water for at least 15 minutes while removing contaminated
clothing and shoes. Get medical aid if irritation develops or persists. Wash clothing before reuse. Ingestion:
Do not induce vomiting. If victim is conscious and alert, give 2-4 cupfuls of milk or water.
Get medical aid immediately. Inhalation:
Remove from exposure and move to fresh air immediately. If not breathing, give artificial
respiration. If breathing is difficult, give oxygen. Get medical aid. Do NOT use mouth-to-mouth
resuscitation. If breathing has ceased apply artificial respiration using oxygen and a suitable mechanical
device such as a bag and a mask. Notes to Physician:
Treat symptomatically and supportively.
As in any fire, wear a self-contained breathing apparatus in pressure-demand,
MSHA/NIOSH (approved or equivalent), and full protective gear. During a fire, irritating and highly toxic
gases may be generated by thermal decomposition or combustion. Extinguishing Media:
Use extinguishing media most appropriate for the surrounding fire. Flash Point:
Not applicable. Autoignition Temperature:
Not applicable. Explosion Limits, Lower:
Not available. Upper:
Not available. NFPA Rating:
(estimated) Health: 2; Flammability: 0; Instability: 0
Use proper personal protective equipment as indicated in Section 8. Spills/Leaks:
Vacuum or sweep up material and place into a suitable disposal container. Clean up spills
immediately, observing precautions in the Protective Equipment section. Avoid generating dusty
conditions. Provide ventilation.
Wash thoroughly after handling. Remove contaminated clothing and wash before reuse. Use
with adequate ventilation. Minimize dust generation and accumulation. Avoid contact with skin and eyes.
Keep container tightly closed. Avoid ingestion and inhalation. Storage:
Store in a cool, dry, well-ventilated area away from incompatible substances.
Section 8 - Exposure Controls, Personal Protection
Facilities storing or utilizing this material should be equipped with an eyewash
facility and a safety shower. Use adequate ventilation to keep airborne concentrations low. Exposure Limits
OSHA - Final PELs
OSHA Vacated PELs:
Ampicillin Sodium: No OSHA Vacated PELs are listed for this chemical. Personal Protective Equipment Eyes:
Wear appropriate protective eyeglasses or chemical safety goggles as described by OSHA's eye
and face protection regulations in 29 CFR 1910.133 or European Standard EN166. Skin:
Wear appropriate protective gloves to prevent skin exposure. Clothing:
Wear appropriate protective clothing to prevent skin exposure. Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard
EN 149. Always use a NIOSH or European Standard EN 149 approved respirator when necessary.
Section 9 - Physical and Chemical Properties
white to off-white Odor:
none reported pH:
8.0-10.0 @ 1% solu. Vapor Pressure:
Not applicable. Vapor Density:
Not available. Evaporation Rate:
Not applicable. Viscosity:
Not applicable. Boiling Point:
Not available. Freezing/Melting Point:
419 deg F Decomposition Temperature:
Not available. Solubility:
Very soluble in water. Specific Gravity/Density:
Not available. Molecular Formula:
C16H18N3O4SNa Molecular Weight:
Stable under normal temperatures and pressures. Conditions to Avoid:
High temperatures, incompatible materials, dust generation, moisture. Incompatibilities with Other Materials:
Strong oxidizers. Hazardous Decomposition Products:
Carbon monoxide, oxides of nitrogen, oxides of sulfur, irritating
and toxic fumes and gases, carbon dioxide. Hazardous Polymerization:
Has not been reported.
69-52-3: XH8400000 LD50/LC50:
Oral, mouse: LD50 = >5314 mg/kg;
Oral, rat: LD50 = >5314 mg/kg; Carcinogenicity:
CAS# 69-52-3: Not listed by ACGIH, IARC, NIOSH, NTP, or OSHA. Epidemiology:
No information available. Teratogenicity:
No information available. Reproductive Effects:
No information available.
No information available. Mutagenicity:
No information available. Other Studies:
See actual entry in RTECS for complete information.
No data available. No information available. Environmental:
No information reported. Physical:
No information available. Other:
Chemical waste generators must determine whether a discarded chemical is classified as a hazardous
waste. US EPA guidelines for the classification determination are listed in 40 CFR Parts 261.3.
Additionally, waste generators must consult state and local hazardous waste regulations to ensure
complete and accurate classification. RCRA P-Series:
None listed. RCRA U-Series:
CAS# 69-52-3 is not listed on the TSCA inventory. It is for research and development use only. Health & Safety Reporting List
None of the chemicals are on the Health & Safety Reporting List. Chemical Test Rules
None of the chemicals in this product are under a Chemical Test Rule. Section 12b
None of the chemicals are listed under TSCA Section 12b. TSCA Significant New Use Rule
None of the chemicals in this material have a SNUR under TSCA. SARA
CERCLA Hazardous Substances and corresponding RQs
None of the chemicals in this material have an RQ. SARA Section 302 Extremely Hazardous Substances
None of the chemicals in this product have a TPQ. Section 313
No chemicals are reportable under Section 313. Clean Air Act:
This material does not contain any hazardous air pollutants. This material does not contain any Class 1
Ozone depletors. This material does not contain any Class 2 Ozone depletors. Clean Water Act:
None of the chemicals in this product are listed as Hazardous Substances under the CWA. None of the
chemicals in this product are listed as Priority Pollutants under the CWA. None of the chemicals in this
product are listed as Toxic Pollutants under the CWA. OSHA:
None of the chemicals in this product are considered highly hazardous by OSHA. STATE
CAS# 69-52-3 is not present on state lists from CA, PA, MN, MA, FL, or NJ.
California No Significant Risk Level: None of the chemicals in this product are listed.
European Labeling in Accordance with EC Directives
XN Risk Phrases:
R 42/43 May cause sensitization by inhalation and
S 20 When using do not eat or drink.
S 24/25 Avoid contact with skin and eyes.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
S 28B After contact with skin, wash immediately with
plenty of water and soap.
WGK (Water Danger/Protection)
CAS# 69-52-3: No information available. Canada - DSL/NDSL
None of the chemicals in this product are listed on the DSL or NDSL list. Canada - WHMIS
This product has a WHMIS classification of D2B. Canadian Ingredient Disclosure List
MSDS Creation Date:
7/13/1999 Revision #2 Date:
The information above is believed to be accurate and represents the best information currently available to us. However, we make no
warranty of merchantability or any other warranty, express or implied, with respect to such information, and we assume no liability
resulting from its use. Users should make their own investigations to determine the suitability of the information for their particular
purposes. In no event shall Fisher be liable for any claims, losses, or damages of any third party or for lost profits or any special,
indirect, incidental, consequential or exemplary damages, howsoever arising, even if Fisher has been advised of the possibility of such
Palliativmedizinische Leitlinien Erarbeitet im Qualitätszirkel „Palliativmedizin und Hospizarbeit“ in Mainz Angaben zu Dosierungen und Applikationsformen in diesen Leitlinien sind sorgfältig geprüft, ent- binden den Benutzer jedoch nicht davon, sich selbst von der korrekten Indikationsstellung, sowie der Anwendung und Dosierung der Präparate zu überzeugen, insbesondere auch durch P
NEWS RELEASE Antares’ Oxybutynin Gel Product Approved by FDA for the Treatment of Overactive Bladder -- Novel Formulation Provides Convenience, Efficacy and Excellent Tolerability -- Watson to Launch Product in Spring 2012 -- PARSIPPANY, NJ and EWING, NJ – December 8, 2011 -- Watson Pharmaceuticals, Inc. (NYSE: WPI) and Antares Pharma, Inc. (NYSE Amex: AIS) today ann